高截留膜血液透析在心脏骤停复苏后休克早期的血流动力学效能:HYPERDIA试验
该随机开放标签试验纳入35例心脏骤停复苏后休克患者(需去甲肾上腺素或肾上腺素输注>1 mg/h),实验组在ICU入住后48小时内接受2次高截留膜连续静脉-静脉血液透析(HCO-CVVHD),对照组必要时接受标准膜连续静脉-静脉血液滤过(CVVH)。主要终点为休克缓解时间(以儿茶酚胺输注时长评估),两组28天死亡率分别为64.7%和72.2%(p=0.72),儿茶酚胺停用概率相似(logrank检验p=0.67),28天无儿茶酚胺天数分别为25.1 [0, 26.5]和24.5 [0, 26.2](p=0.65)。每日血管活性药物剂量、动脉压和液体平衡均无差异。
要点
- 心脏骤停复苏后休克患者早期接受HCO-CVVHD,28天死亡率64.7% vs 对照组72.2%(p=0.72),无显著差异。
- HCO-CVVHD组与对照组儿茶酚胺停用概率相似(logrank检验p=0.67),未缩短休克持续时间。
- 28天无儿茶酚胺天数HCO-CVVHD组25.1 [0, 26.5] vs 对照组24.5 [0, 26.2](p=0.65),无显著差异。
- 两组每日血管活性药物剂量、动脉压和液体平衡均无差异。
- HCO-CVVHD组在ICU入住后48小时内接受2次治疗,对照组必要时接受标准膜CVVH。
适用人群与场景
- 心脏骤停复苏后休克患者,定义为需要去甲肾上腺素或肾上腺素输注>1 mg/h。
- 纳入标准为心脏骤停复苏后出现急性循环衰竭。
诊断标准与关键阈值
- 复苏后休克定义:需要去甲肾上腺素或肾上腺素输注>1 mg/h。
处置流程与药物剂量
- 实验组:ICU入住后48小时内接受2次高截留膜连续静脉-静脉血液透析(HCO-CVVHD)治疗。
- 对照组:必要时接受标准膜连续静脉-静脉血液滤过(CVVH)。
研究设计与关键结果
- 随机开放标签试验,纳入35例患者,HCO-CVVHD组17例(中位年龄68.4岁,59%男性),对照组18例(中位年龄66.3岁,83%男性)。
- 主要终点休克缓解时间(儿茶酚胺输注时长)两组相似(logrank检验p=0.67)。
- 28天死亡率HCO-CVVHD组64.7% vs 对照组72.2%(p=0.72)。
- 28天无儿茶酚胺天数HCO-CVVHD组25.1 [0, 26.5] vs 对照组24.5 [0, 26.2](p=0.65)。
- 每日血管活性药物剂量、动脉压和液体平衡两组无差异。
证据类型、等级与局限
- 随机开放标签试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在心脏骤停复苏后休克患者中,早期HCO-CVVHD未缩短休克持续时间,对血流动力学无显著影响,不支持将其用于改善此类患者的血流动力学状态。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: After resuscitation of cardiac arrest (CA), an acute circulatory failure occurs in about 50% of cases, which shares many characteristics with septic shock. Most frequently, supportive treatments are poorly efficient to prevent multiple organ failure and death. We evaluated whether an early plasma removal of inflammatory mediators using high cut-off continuous veno-venous hemodialysis (HCO-CVVHD) could improve hemodynamic status and outcome of these patients.
PATIENTS AND METHODS: We performed a randomized open-label trial. Patients with post-cardiac arrest shock (defined as requirement of norepinephrine or epinephrine infusion > 1 mg/h) were included. The experimental group received 2 distinct sessions of HCO-CVVHD during the first 48 h following ICU admission. The control group received continuous veno-venous hemofiltration (CVVH) with standard membranes if needed. The primary endpoint was the delay to shock resolution asssessed by the length of catecholamine infusion. Number of vasopressors-free days at day 28, arterial blood pressure measures every 6-hours, daily fluid balance and mortality (ICU and day-28) were evaluated as secondary endpoints.
RESULTS: 35 patients were included: 17 (median age 68.4, 59% male) in the HCO-CVVHD group and 18 (median age 66.3, 83% male) in the control group. Baseline characteristics did not differ between the two groups. Day-28 mortality rate was 64.7% and 72.2% in the HCO-CVVHD and control group, respectively (p = 0.72). Probability of vasopressors discontinuation over time was similar in the two groups (p for logrank test = 0.67). Number of day-28 catecholamine-free days was 25.1 [0, 26.5] and 24.5 [0, 26.2] in the HCO-CVVHD and control group, respectively (p = 0.65). No difference was observed regarding the daily-dose of vasopressors, arterial pressure profile and fluid balance.
CONCLUSION: In cardiac arrest patients, HCO-CVVHD did not decrease the lenght of post-resuscitation shock and had no significant effect on hemodynamic profile.
REGISTRATION: NCT00780299.
参考来源
- Geri G, Grimaldi D, Seguin T, et al. Hemodynamic efficiency of hemodialysis treatment with high cut-off membrane during the early period of post-resuscitation shock: The HYPERDIA trial. Resuscitation. 2019. PMID: 30974188. doi:10.1016/j.resuscitation.2019.03.045
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。